DDInter1702 DDInter504
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Desipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Desipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxcarbazepine
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Desipramine
Sorafenib {u} (Compound) binds {v} (Gene) HTR2C
HTR2C {u} (Gene) is bound by {v} (Compound) Desipramine
Sorafenib {u} (Compound) downregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Desipramine
Sorafenib {u} (Compound) upregulates {v} (Gene) SYNGR3
SYNGR3 {u} (Gene) is upregulated by {v} (Compound) Desipramine
Sorafenib {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Desipramine
Sorafenib {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Desipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Desipramine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Desipramine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Desipramine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Desipramine (Compound)
Sorafenib (Compound) binds HTR2C (Gene) and HTR2C (Gene) is bound by Desipramine (Compound)
Sorafenib (Compound) downregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Desipramine (Compound)
Sorafenib (Compound) upregulates SYNGR3 (Gene) and SYNGR3 (Gene) is upregulated by Desipramine (Compound)
Sorafenib (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Desipramine (Compound)
Sorafenib (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Desipramine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Triflupromazine (Compound) and Triflupromazine (Compound) resembles Desipramine (Compound)